BCL2 and B-cell chronic lymphocytic leukemia: The fairly frequently reoccurring mechanism of treatment resistance in lymphoid malignancies, especially CLL, which is clinically sensitive to VTX monotherapy [33,34,35], is the previously mentioned BCL-2 mutation.